What has Joe Rogan actually said about peptides?
The answer is shorter than the internet wants it to be. In the material we verified, Rogan has named one peptide he took: BPC-157. He said it on episode 1580 of The Joe Rogan Experience, with the comedian Andrew Schulz, on 17 December 2020. The story was about his elbow: a tendonitis he could not shift, gone in two weeks on BPC-157, and "athletes swear by" it. Schulz's reply, "Wolverine shit", gave the compound the nickname it still carries.
Two details matter. Rogan said "my doctor actually told me about peptides a long time ago", which places his introduction to the category in a clinic rather than a forum, years before 2020. And it was an anecdote, not a protocol: no dose, no route, no product, no duration beyond the two weeks. He returned to BPC-157 in 2021 on episode 1683 with Andrew Huberman, and has talked about NAD+ and NMN supplementation, covered below, again without naming a product or a dose.
The most consequential peptide conversation on the show concerned someone else's habits. On 27 February 2026 his guest was Robert F. Kennedy Jr, the Secretary of Health and Human Services, who said "I'm a big fan of peptides", said he had used them himself, and promised the FDA would restore access to around fourteen of them. That episode changed peptide regulation in America more than any trial has.
Joe Rogan peptides: what the stack pages get wrong
Search the phrase and you will find dozens of pages listing a Joe Rogan peptide stack. Almost all are affiliate content: a vendor link sits under the list, which matches what the vendor sells. BPC-157 leads, because there is a quote for it. Then TB-500, sold as BPC-157's partner. Then CJC-1295 and ipamorelin, MK-677, sermorelin, and lately retatrutide, because the GLP-1 drugs are where the traffic is.
Here is the plain statement those pages avoid. In nothing we verified has Rogan said he takes TB-500, CJC-1295, ipamorelin, MK-677, sermorelin or retatrutide. Not with Schulz, not with Huberman, not with Kennedy. Those names are attached to his by inference from what the culture around the show uses, and a page that does not say so is guessing at a famous man's medicine cabinet to sell you something. We describe each compound below anyway, because it is what the searcher wants, under the label that matters: what circulates around the show, not what Joe Rogan takes.
The six compounds the stack pages attach to his name
TB-500 is sold as a synthetic fragment of thymosin beta-4, a 43-amino-acid protein involved in actin regulation and cell migration. The full-length protein has been through randomised trials as a topical eye drop for corneal healing, with mixed results; the injectable fragment sold for tendons has no human trial at all. It rides with BPC-157 as the Wolverine stack on overlapping rodent mechanisms and shares its regulatory history.
CJC-1295 and ipamorelin are growth hormone secretagogues, usually sold as a pair. CJC-1295 is a growth hormone-releasing hormone analogue whose drug-affinity-complex version binds albumin and lasts days rather than minutes; one name covers both versions. Its human record is a 2006 pharmacokinetic study showing sustained rises in growth hormone and IGF-1, and nothing on any outcome anyone buys it for. Ipamorelin acts on the ghrelin receptor and is genuinely selective, sparing cortisol and prolactin; its human data are discontinued mid-stage trials for gut motility after surgery.
MK-677, or ibutamoren, is not a peptide but an oral small molecule that mimics ghrelin. It has the best human data on this list, and the data are why it was abandoned: a two-year randomised trial in healthy older adults raised IGF-1 to young-adult levels and added roughly a kilogram of lean mass, with no gain in strength or function and worse fasting glucose. An Alzheimer's trial was negative. It is investigational, unlawful as a supplement in the United States, and prohibited in sport.
Sermorelin is the shortest active fragment of growth hormone-releasing hormone and the only compound here with an approval history. Marketed as Geref for paediatric growth hormone deficiency, it left the US market in 2008 for commercial rather than safety reasons and survives through patient-specific compounding, mostly in anti-ageing clinics, where the evidence for adult wellness uses is thin.
Retatrutide is the odd one out: a triple agonist at the GIP, GLP-1 and glucagon receptors, developed by Lilly for obesity. Its 48-week phase 2 trial produced the largest average weight reduction reported for a drug, roughly a quarter of body weight at the highest dose against about two percent on placebo; phase 3 is where durability and safety get tested. It is approved nowhere, so anything sold under the name is unapproved material of unverified identity, and it appears on Rogan pages because GLP-1 traffic is enormous, not because he has ever mentioned it.
BPC-157: the rodent programme and the trial that does not exist
BPC-157 is a fifteen-amino-acid synthetic peptide described as a fragment of a protective protein in gastric juice. Its literature is large and strange. Well over a hundred rodent studies, most from one Zagreb group over three decades, report benefit in nearly every injury model tried: transected Achilles tendon, crushed muscle, cut ligament, colitis, nerve injury. The direction of effect never wavers, the signature either of a fundamental repair signal or of a programme that does not publish its nulls, and an outsider cannot tell which.
The human side is close to empty. There is no published randomised, placebo-controlled trial of BPC-157 in humans for any indication. An oral formulation entered early clinical testing for inflammatory bowel disease around two decades ago and its efficacy results never reached the peer-reviewed literature. Since then the record is a handful of small uncontrolled pilot reports from one US group, including a 2025 intravenous safety pilot in a couple of healthy adults, with no human pharmacokinetic profile and no independent replication.
That is the compound behind the most famous peptide anecdote in America. Rogan's elbow story is compatible with BPC-157 working; rodent tendons heal over roughly the same fortnight. It is equally compatible with it doing nothing.
Why a two-week elbow story cannot separate the drug from the calendar
Start with the word. Tendonitis implies inflammation, and since a widely cited 2002 BMJ editorial sports medicine has largely abandoned the term for chronic tendon pain, because biopsies show a degenerative matrix with few inflammatory cells. The correct word is tendinopathy, and its natural history is the whole problem: lateral elbow tendinopathy, the tennis elbow of anyone who grips hard for a living, resolves on its own in most people.
The two best-known randomised trials of tennis elbow, from the Netherlands in 2002 and Australia in 2006, each included a wait-and-see arm that got advice and nothing else. By one year roughly eight or nine in ten of those untreated patients rated themselves recovered or much improved, and corticosteroid injection, the fastest early relief, did worse than doing nothing. Tendons get better on their own, slowly and unevenly, regardless of what was started on the first bad day.
Then add regression to the mean. People start a new treatment when pain is at its worst, and the worst is by definition the point from which measurements move back toward average. Add the rest, reduced loading and attention that come with any new treatment, and the expectation of a fix. A two-week improvement after all that is what you would predict whether the vial held BPC-157 or saline. That is not a claim it was saline; it is why a placebo arm exists. None of this touches Rogan's honesty. He reported what he experienced, as a story; the audience turned one unblinded observation into a mechanism.
BPC-157's regulatory record: September 2023, April 2026, July 2026
In September 2023 the FDA placed BPC-157 in Category 2 of its section 503A bulk substances review, the category for significant safety risk, alongside TB-500, CJC-1295, ipamorelin and fifteen others, barring compounding pharmacies from preparing them. The stated basis was not evidence of harm but an unfilled file: no human pharmacokinetics, unresolved immunogenicity questions, no assessment of chronic exposure.
On 15 April 2026 the agency reversed course in form if not yet in substance, announcing advisory meetings and moving twelve peptides out of Category 2, not into Category 1 but into a limbo where they remain uncompoundable. Kennedy called it "a long-overdue action to restore science, accountability and the rule of law" that would "shift demand away from the black market". Pat Carroll of Hims & Hers, a telehealth company with an obvious commercial stake, called it "an important step toward moving these treatments out of the gray market".
On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee met under docket FDA-2025-N-6895 and voted 8 to 6, with one abstention, in favour of BPC-157 for ulcerative colitis. Note the indication: not tendons, not recovery, but the one condition in which the compound was ever tested in humans, with results never published. KPV and TB-500 also passed 8 to 6, MOTS-c 7 to 5, semax 8 to 5, epitalon 7 to 5; DSIP was rejected 6 to 7. A second meeting on five more peptides is due before March 2027.
The vote is advisory. The FDA's own career scientists told the committee they lacked the evidence to assess safety or effectiveness for any of the substances, and that without accepted chemical definitions the identity, quality and comparability of one vial against the next could not be established. Category 1 placement requires notice-and-comment rulemaking, realistically eight to twelve months, into 2027. BPC-157 still cannot lawfully be compounded, is approved nowhere, and is not a supplement.
NAD+ is a coenzyme, not a peptide
Rogan has discussed NAD+ and NMN supplementation, and the stack pages file NAD+ under peptides. It is not one. Nicotinamide adenine dinucleotide is two nucleotides joined through their phosphates, with no amino acids in it, and one of the cell's central coenzymes: it shuttles electrons in energy metabolism and feeds the sirtuins, the PARP repair enzymes and the CD38 hydrolase that consumes most of it. Tissue NAD+ falls with age in animals and in limited human data, which is the rationale for supplementing.
The oral route relies on precursors, because NAD+ itself is broken down outside the cell before it can enter one. Nicotinamide riboside was shown in 2016 to raise blood NAD+ in humans; a six-week crossover trial in 2018 raised blood-cell NAD+ by around sixty percent, was well tolerated, and did not significantly change blood pressure or arterial stiffness. A ten-week NMN trial in prediabetic postmenopausal women in 2021 improved a laboratory measure of muscle insulin sensitivity and nothing else measured; a twelve-week riboside trial in obese men found no effect on insulin sensitivity, energy expenditure or body composition. Precursors reliably raise the biomarker and have so far produced modest or null effects on anything a person would notice.
Intravenous NAD+, the clinic drip, has a thinner record still. The only substantive human study is a small pharmacokinetic pilot of a six-hour infusion in healthy adults, in which plasma NAD+ did not rise for roughly the first two hours, implying rapid uptake or breakdown, and metabolites appeared in urine. There is no randomised trial of intravenous NAD+ for fatigue, addiction, cognition or ageing, no dose-finding, and no comparison against oral precursors costing a fraction as much. The flushing and chest tightness people describe during a drip have never been characterised in a controlled setting, and the drip is not an approved drug product for any indication.
The Kennedy episode: how a podcast became FDA policy
On 27 February 2026 Rogan was mostly the listener. Kennedy said "I'm a big fan of peptides", said he had used them, and framed the 2023 decision with a line quoted ever since: "We created the gray market". His argument was that barring compounding had pushed demand toward unregulated research-use-only vials, and that restoring it would pull demand back.
Six weeks later the FDA did what the Secretary had promised. Coverage in NPR on 31 March, STAT on 15 April and BioPharma Dive drew the line from the podcast to the April action directly, and the July committee was the next step on the same path. A cabinet secretary announced a regulatory outcome on a podcast and the agency he oversees then worked toward it, with the scientific review arriving after the political commitment rather than before.
The grey-market argument has a real point and a real hole. The point: a compounded product under a prescription is made to a standard, and a research-use-only vial is not. The hole: the grey market did not begin in 2023. Rogan's elbow story is from 2020, when compounded BPC-157 was still dispensed through clinics, and "athletes swear by" it describes a market that already existed. Restoring compounding changes who sells an unproven compound; it does not generate the trial that would show whether it works. A non-binding 8 to 6 vote over the reviewers' objection, followed by rulemaking into 2027, is not access restored. It is a political promise part-way through a process that has produced no new data.
The doping angle for fighters and tested athletes
Rogan has been a UFC commentator for more than two decades, and a large share of his audience trains, competes or is tested. For them there is a simpler question than evidence. BPC-157 has been on the WADA Prohibited List since 2022 under S0, the heading for substances with no current approval for human use. Thymosin beta-4 and its derivatives, TB-500 named explicitly, sit under S2 with the growth factors, as do CJC-1295, ipamorelin, sermorelin and MK-677 as growth hormone-releasing factors and secretagogues. Retatrutide, unapproved, falls under S0.
The UFC's anti-doping programme, run by USADA from 2015 to the end of 2023 and by a successor programme since, applies the WADA list. Violations are strict liability: the athlete answers for what is in the sample regardless of intent, and a mislabelled research-use-only vial is not a defence. Tested athletes have been sanctioned for BPC-157.
A prohibition is not a finding that a compound works. Substances go on the list because they are unapproved or belong to a class, not because a trial showed an advantage. That cuts both ways for the fighter reading a stack page: the ban does not mean it is worth the risk, and the absence of a trial does not mean the test will miss it.
What a podcast anecdote is, and what it is not
One person's account of one injury improving is a case report with no chart: a sample size of one, no control, no blinding, an outcome judged by the person most invested in it, and a start date chosen by pain, which guarantees regression to the mean. It carries no information about effect size, dose, duration or who else it would help. It is a reason to run a trial, and the trial has not been run.
It is also, in Rogan's case, an unusually powerful hypothesis generator. An audience of millions per episode heard the story, and the phrase Schulz coined is now a product category. That influence is real, and it is not his fault; he told a story about his elbow. The fault lies with the pages that turned it into a stack, added compounds he never named, and put a checkout button under it.
Once the famous name comes off the vial, the evidence looks like this: one peptide he took, with a rodent literature and no human trial; one coenzyme he has discussed, with modest trial data for oral precursors and none for the drip; and six compounds attached to him by inference, none with a human efficacy trial for the uses claimed. That is the honest answer to what peptides Joe Rogan uses: shorter than the affiliate version, and true.